| Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma (NCT05272384) | National Cancer Institute (NCI) | 2022-11-03 |
| Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma (NCT04933539) | National Cancer Institute (NCI) | 2022-10-31 |
| PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma (NCT05286814) | National Cancer Institute (NCI) | 2022-10-24 |
| A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies (NCT04923178) | National Cancer Institute (NCI) | 2022-10-24 |
| Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis (NCT05185947) | National Cancer Institute (NCI) | 2022-10-13 |
| Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative (NCT04929041) | National Cancer Institute (NCI) | 2022-10-07 |
| Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene (NCT05372614) | National Cancer Institute (NCI) | 2022-10-05 |
| Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET) (NCT04086485) | National Cancer Institute (NCI) | 2022-10-03 |
| Testing the Effect of the Broccoli Seed and Sprout Extract, Avmacol ES, on the Cancer Causing Substances of Tobacco in Heavy Smokers (NCT05121051) | National Cancer Institute (NCI) | 2022-09-21 |
| Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer (NCT05172245) | National Cancer Institute (NCI) | 2022-09-19 |
| Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer (NCT05276973) | National Cancer Institute (NCI) | 2022-09-08 |
| 18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy (NCT05155046) | National Cancer Institute (NCI) | 2022-08-31 |
| Hyperspectral Analysis of Sweat Metabolite Biometrics for Real-Time Detection of COVID-19 (NCT05044780) | National Cancer Institute (NCI) | 2022-08-30 |
| Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, AXIOM Trial (NCT05333458) | National Cancer Institute (NCI) | 2022-08-29 |
| Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes (NCT04802161) | National Cancer Institute (NCI) | 2022-08-24 |
| Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma (NCT05155033) | National Cancer Institute (NCI) | 2022-08-18 |
| Comprehensive Molecular and Clinical Evaluation of Pediatric and Adult MDS (NCT05350748) | National Cancer Institute (NCI) | 2022-08-18 |
| Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery (NCT05111574) | National Cancer Institute (NCI) | 2022-08-11 |
| Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer (NCT04929028) | National Cancer Institute (NCI) | 2022-08-09 |
| Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis (NCT04847453) | National Cancer Institute (NCI) | 2022-08-03 |
| Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer (NCT05111561) | National Cancer Institute (NCI) | 2022-08-02 |
| Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer (NCT05353439) | National Cancer Institute (NCI) | 2022-07-27 |
| Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (NCT05172258) | National Cancer Institute (NCI) | 2022-07-26 |
| Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation (NCT05308446) | National Cancer Institute (NCI) | 2022-07-19 |
| Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma (NCT05019716) | National Cancer Institute (NCI) | 2022-07-13 |
| Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial (NCT05142241) | National Cancer Institute (NCI) | 2022-07-11 |
| Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy (NCT04963153) | National Cancer Institute (NCI) | 2022-07-07 |
| Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer (NCT04576091) | National Cancer Institute (NCI) | 2022-07-06 |
| Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy (NCT05295589) | National Cancer Institute (NCI) | 2022-06-30 |
| Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung (NCT05058651) | National Cancer Institute (NCI) | 2022-06-28 |
| Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON). (NCT05012098) | National Cancer Institute (NCI) | 2022-06-21 |
| Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer (NCT04981509) | National Cancer Institute (NCI) | 2022-06-10 |
| Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study (NCT05092958) | National Cancer Institute (NCI) | 2022-06-03 |
| A Natural History Study of Children and Adults With Olfactory Neuroblastoma (NCT04755205) | National Cancer Institute (NCI) | 2022-06-02 |
| Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma (NCT05112601) | National Cancer Institute (NCI) | 2022-06-02 |
| A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG) (NCT05099003) | National Cancer Institute (NCI) | 2022-05-31 |
| Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant (NCT04815356) | National Cancer Institute (NCI) | 2022-05-23 |
| Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies (NCT05327023) | National Cancer Institute (NCI) | 2022-05-23 |
| Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC) (NCT05237934) | National Cancer Institute (NCI) | 2022-04-25 |
| Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies (NCT04888936) | National Cancer Institute (NCI) | 2022-04-25 |
| Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System (NCT05211336) | National Cancer Institute (NCI) | 2022-04-19 |
| PT-112 in Subjects With Thymoma and Thymic Carcinoma (NCT05104736) | National Cancer Institute (NCI) | 2022-04-06 |
| Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas (NCT04933617) | National Cancer Institute (NCI) | 2022-03-24 |
| Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma (NCT05001880) | National Cancer Institute (NCI) | 2022-03-22 |
| Pomalidomide Treatment in Patients With Kaposi Sarcoma (NCT04577755) | National Cancer Institute (NCI) | 2022-03-18 |
| Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma (NCT04729959) | National Cancer Institute (NCI) | 2022-03-11 |
| T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers (NCT05035407) | National Cancer Institute (NCI) | 2022-03-08 |
| Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP) (NCT04896073) | National Cancer Institute (NCI) | 2022-03-07 |
| Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers (NCT04645160) | National Cancer Institute (NCI) | 2022-03-04 |
| Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial (NCT05237947) | National Cancer Institute (NCI) | 2022-03-01 |
| Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M) (NCT06400264) | National Cancer Institute (NCI) | 2022-02-22 |
| Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial (NCT03941860) | National Cancer Institute (NCI) | 2022-02-16 |
| Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC). (NCT04566133) | National Cancer Institute (NCI) | 2022-02-15 |
| Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients (NCT04817241) | National Cancer Institute (NCI) | 2022-02-10 |
| Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy (NCT04494113) | National Cancer Institute (NCI) | 2022-02-08 |
| Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer (NCT04751370) | National Cancer Institute (NCI) | 2022-02-08 |
| Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors (NCT04840589) | National Cancer Institute (NCI) | 2022-02-02 |
| Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, GD2-CAR PERSIST Trial (NCT04539366) | National Cancer Institute (NCI) | 2022-01-25 |
| Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma (NCT04840602) | National Cancer Institute (NCI) | 2022-01-05 |
| Tissue Acquisition and Genomics Analysis of Breast Cancer and Other Gynecologic Malignancies (NCT03762733) | National Cancer Institute (NCI) | 2022-01-04 |
| Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors (NCT05071209) | National Cancer Institute (NCI) | 2021-12-22 |
| Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin (NCT04533750) | National Cancer Institute (NCI) | 2021-12-20 |
| Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients With Prostate Cancer That Has Spread to Bones (NCT04616547) | National Cancer Institute (NCI) | 2021-12-18 |
| Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies (NCT04599634) | National Cancer Institute (NCI) | 2021-12-16 |
| Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer (NCT04941287) | National Cancer Institute (NCI) | 2021-12-15 |
| Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies (NCT04648826) | National Cancer Institute (NCI) | 2021-12-14 |
| Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer (NCT04847466) | National Cancer Institute (NCI) | 2021-12-14 |
| Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV (NCT04902443) | National Cancer Institute (NCI) | 2021-12-10 |
| GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies (NCT05003895) | National Cancer Institute (NCI) | 2021-12-08 |
| Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma (NCT04817254) | National Cancer Institute (NCI) | 2021-12-08 |
| Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas (NCT04750928) | National Cancer Institute (NCI) | 2021-11-29 |
| Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV (NCT04514484) | National Cancer Institute (NCI) | 2021-11-22 |
| Natural History of KSHV-Associated Multicentric Castleman s Disease (NCT04968288) | National Cancer Institute (NCI) | 2021-11-17 |
| Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer (NCT04628767) | National Cancer Institute (NCI) | 2021-11-12 |
| Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome (NCT04652960) | National Cancer Institute (NCI) | 2021-10-21 |
| Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer (NCT04514497) | National Cancer Institute (NCI) | 2021-10-20 |
| Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies (NCT04847063) | National Cancer Institute (NCI) | 2021-10-19 |
| A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma (NCT04708418) | National Cancer Institute (NCI) | 2021-10-15 |
| CAR-Multicenter Analysis (CAR-MA): Retrospective Study to Characterize CAR T-cell Outcomes and Related Toxicities in Children and Young Adults With B-ALL (NCT05440409) | National Cancer Institute (NCI) | 2021-10-14 |
| Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (NCT04759586) | National Cancer Institute (NCI) | 2021-10-05 |
| A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers (NCT04708470) | National Cancer Institute (NCI) | 2021-10-05 |
| Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma (NCT04941274) | National Cancer Institute (NCI) | 2021-09-29 |
| Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies (NCT04959175) | National Cancer Institute (NCI) | 2021-09-23 |
| A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors (NCT04826341) | National Cancer Institute (NCI) | 2021-09-20 |
| Precision-Based Genomics in Prostate Cancer (NCT04706663) | National Cancer Institute (NCI) | 2021-09-14 |
| Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer (NCT04989283) | National Cancer Institute (NCI) | 2021-09-09 |
| Needs Assessment for Individuals and Families Affected by Dyskeratosis Congenita (DC) and Related Telomere Biology Disorders (TBD) (NCT04959188) | National Cancer Institute (NCI) | 2021-09-09 |
| Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL) (NCT04301076) | National Cancer Institute (NCI) | 2021-08-31 |
| Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma (NCT04751383) | National Cancer Institute (NCI) | 2021-08-31 |
| Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer (NCT04491942) | National Cancer Institute (NCI) | 2021-08-25 |
| Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment (NCT04557956) | National Cancer Institute (NCI) | 2021-08-19 |
| Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines (NCT04535401) | National Cancer Institute (NCI) | 2021-08-13 |
| Managing Cancer and Living Meaningfully (CALM) Therapy in Individuals Diagnosed With a Primary Brain Tumor (NCT04852302) | National Cancer Institute (NCI) | 2021-08-11 |
| Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial (NCT04704661) | National Cancer Institute (NCI) | 2021-08-09 |
| National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer (NCT04145141) | National Cancer Institute (NCI) | 2021-07-28 |
| Connect for Cancer Prevention Study (Connect) (NCT04609072) | National Cancer Institute (NCI) | 2021-07-26 |
| Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland (NCT04530552) | National Cancer Institute (NCI) | 2021-07-23 |
| Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors (NCT04750954) | National Cancer Institute (NCI) | 2021-07-22 |
| Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma (NCT04739813) | National Cancer Institute (NCI) | 2021-07-09 |
| Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors (NCT04538378) | National Cancer Institute (NCI) | 2021-07-07 |